NVS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 23, 2026Sponsor estimate | NCT05399992Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVDNovartis Pharmaceuticals · Primary Hypercholesterolemia | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · Non-Small-Cell Lung Carcinoma | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07821411A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanNovartis Pharmaceuticals · Multiple Sclerosis | NVSLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 23, 2026Sponsor estimateNo phase registeredNCT05399992Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVDNovartis Pharmaceuticals · Primary HypercholesterolemiaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · Non-Small-Cell Lung CarcinomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07821411A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanNovartis Pharmaceuticals · Multiple SclerosisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 1NCT00819546RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSRichard Stone, MD · Acute Myeloid LeukemiaActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimateNo phase registeredNCT05009160DreaMS - Validation Study 1Research Center for Clinical Neuroimmunology and Neuroscience Basel · Multiple SclerosisActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT06964958177LuPSMA in Renal Cell CarcinomaDana-Farber Cancer Institute · Renal Cell CarcinomaActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2026Sponsor estimatePhase 2NCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive...Novartis Pharmaceuticals · Metastatic Hormone-sensitive Prostate CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimateNo phase registeredNCT06092879Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in...Novartis Pharmaceuticals · Chronic Myeloid LeukemiaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimateNo phase registeredNCT05776888Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 YearsNovartis Pharmaceuticals · Relapsing Multiple SclerosisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimateNo phase registeredNCT05274425A 24-week rPMS Study in Real-world Setting for EnerzairNovartis Pharmaceuticals · AsthmaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 2NCT05849298A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNovartis Pharmaceuticals · Prostatic NeoplasmActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 24, 2026Sponsor estimateNo phase registeredNCT05217810A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®Novartis Pharmaceuticals · AsthmaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT05870579[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerNovartis Pharmaceuticals · Breast CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 4NCT06372925Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial InfarctionNovartis Pharmaceuticals · Plaque, AtheroscleroticActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT06388941Iptacopan in Patients With ANCA Associated VasculitisNovartis Pharmaceuticals · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05714891Neoadjuvant Platform Trial in Non-Small Cell Lung CancerCanadian Cancer Trials Group · NSCLCActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 4NCT06249165VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart DiseaseDuke University · Atherosclerotic Cardiovascular DiseaseActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06517732Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe...Novartis Pharmaceuticals · Hidradenitis SuppurativaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06643936E3 Diabetes - Closing the Gap in Diabetes ControlRush University Medical Center · Type 2 DiabetesActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 2NCT04894370Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal CarcinomaCentre Hospitalier Universitaire de Besancon · Squamous Cell Anal CarcinomaActive, not recruitingNVSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2027Sponsor estimatePhase 1NCT04857372A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid TumorsNovartis Pharmaceuticals · MesotheliomaActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2027Sponsor estimatePhase 3NCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesNovartis Pharmaceuticals · Acute Coronary SyndromeActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 25, 2027Sponsor estimatePhase 1/Phase 2NCT04699188Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis Pharmaceuticals · KRAS G12C Mutant Solid TumorsActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2027Sponsor estimatePhase 3NCT05038735Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced...Novartis Pharmaceuticals · Breast CancerActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 2NCT04544189Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and...Novartis Pharmaceuticals · Breast NeoplasmsActive, not recruitingNVSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.